The 24.2% Number
The headline figure from the Retatrutide Phase 2 trial is 24.2% — the mean percentage of body weight lost by participants receiving the highest dose (12 mg weekly) over 48 weeks. This number deserves careful contextualization because its magnitude is genuinely historic.
To translate to absolute terms: a participant starting at 240 lbs would, on average, lose approximately 58 lbs in 48 weeks. A participant starting at 300 lbs would lose approximately 73 lbs. These are transformational changes in body composition — changes that historically could only be achieved through major bariatric surgery.
24.2% weight loss in 48 weeks. No plateau. For context: bariatric surgery (Roux-en-Y gastric bypass) typically produces 25–35% excess body weight loss. Retatrutide is approaching surgical territory pharmacologically.
Historical Context — A Timeline of Records
To appreciate why 24.2% is historic, it helps to trace how pharmaceutical weight loss has advanced:
- Orlistat (1999): First major pharmacological weight loss agent — ~5% mean body weight loss
- Phentermine/topiramate (2012): ~10% mean weight loss at highest approved dose
- Semaglutide 2.4 mg (STEP-1, 2021): 14.9% mean weight loss at 68 weeks — broke all previous records
- Tirzepatide 15 mg (SURMOUNT-1, 2022): 20.9% at 72 weeks — broke semaglutide's record
- Retatrutide 12 mg (NEJM Phase 2, 2023): 24.2% at only 48 weeks — broke tirzepatide's record at a shorter timepoint
Each successive GLP-1-based compound has broken the record of its predecessor. But the progression from semaglutide (~15%) to tirzepatide (~21%) to Retatrutide (~24%) at 48 weeks — and still climbing — suggests that the glucagon receptor adds qualitatively different efficacy, not just marginal improvement.
Body Composition Changes
The 24.2% headline is total body weight. Research in this trial and in the broader GLP-1 agonist literature has examined body composition more granularly. Key composition data from the Retatrutide Phase 2 and related research:
- Waist circumference: Mean reduction of 17.5 cm at the highest dose — a large reduction in central/visceral adiposity specifically
- Fat mass: The majority of weight lost is fat mass, consistent with the mechanism (GLP-1-driven appetite reduction + glucagon-driven lipolysis). Muscle mass preservation is an active area of research in the GLP-1 class
- Liver fat: 46% reduction in hepatic fat in the metabolic syndrome subgroup — far beyond what diet alone typically achieves
The No-Plateau Finding — Why It Matters
One of the most scientifically significant aspects of the Phase 2 Retatrutide data is that weight loss had not plateaued at 48 weeks in the highest dose groups. The dose-response curves were still declining steeply at trial end.
This is in contrast to semaglutide, where STEP-1 data showed the weight loss curve beginning to flatten around week 60–68. Tirzepatide similarly approached plateau around weeks 64–72 in SURMOUNT-1.
Retatrutide's still-declining curve at 48 weeks raises the question: where is the biological ceiling? If Phase 3 trials run to 72 or 96 weeks at the 12 mg dose, what will the final weight loss percentage be? Projections based on the Phase 2 trajectory suggest it could reach or exceed 30% mean body weight loss — territory that has only previously been accessible through bariatric surgery.
Research implication: The no-plateau finding is perhaps more scientifically significant than the 24.2% itself. It means the drug has not reached its mechanism's ceiling at 48 weeks — and that Phase 3 long-term data may reveal even greater weight loss potential.
High Responders — More Than 40% Achieved ≥25% Loss
Mean weight loss statistics are, by definition, averages. The distribution of responses in the Retatrutide Phase 2 highest-dose group is particularly striking:
- More than 70% of participants achieved ≥15% body weight loss
- More than 55% achieved ≥20% body weight loss
- More than 40% achieved ≥25% body weight loss
- Some participants achieved weight loss approaching 35%+ — firmly in the range of bariatric surgical outcomes
For comparison, in the semaglutide STEP-1 trial at 68 weeks, only ~32% of participants achieved ≥15% weight loss, and fewer than 10% achieved ≥20%. Retatrutide's response distribution represents a qualitative shift in what pharmacological intervention can achieve across a population.
Beyond the Scale — Full Metabolic Outcomes
While body weight is the primary headline, the Retatrutide Phase 2 trial showed improvements across the complete metabolic health profile:
- Blood pressure: −7 to −9 mmHg systolic reduction at highest doses
- Triglycerides: ~30–35% reduction — clinically significant for cardiovascular risk
- Fasting insulin: Dose-dependent reduction, suggesting improved insulin sensitivity
- Fasting glucose: Meaningful reductions even in non-diabetic participants
- LDL cholesterol: Modest reductions alongside HDL increases
- Liver fat: 46% reduction in the metabolic syndrome subgroup
Research Implications
The Retatrutide Phase 2 weight loss data has profound implications for the trajectory of obesity pharmacology research. It establishes that the glucagon receptor — not just GLP-1 and GIP — is a meaningful target for weight loss, and that multi-receptor agonism can achieve outcomes that each individual receptor cannot approach alone.
For researchers, Retatrutide represents an opportunity to study the highest achievable pharmacological weight loss, the mechanisms behind it (glucagon-driven lipolysis and thermogenesis specifically), and the long-term metabolic consequences of >24% body weight reduction. It is available in research grade from QSC Peptides with verified ≥99% purity.
Buy Retatrutide for Weight Loss Research
Research-grade Retatrutide is available from QSC Peptides (qscpeptide.com) in vial sizes from 5mg to 100mg, shipped from domestic warehouses in the USA, EU, UK, Australia, and Canada. All orders include a Certificate of Analysis. Free shipping worldwide.
Search terms to find QSC's Retatrutide products: buy retatrutide, buy reta, QSC reta, QSC retatrutide, QSC RT10, shop reta, retatrutide USA domestic, reta weight loss peptide.